AR046572A1 - Uso de mejoradores de la transcripcion de enos en la terapia celular de enfermedades cardiacas isquemicas - Google Patents
Uso de mejoradores de la transcripcion de enos en la terapia celular de enfermedades cardiacas isquemicasInfo
- Publication number
- AR046572A1 AR046572A1 ARP040104050A ARP040104050A AR046572A1 AR 046572 A1 AR046572 A1 AR 046572A1 AR P040104050 A ARP040104050 A AR P040104050A AR P040104050 A ARP040104050 A AR P040104050A AR 046572 A1 AR046572 A1 AR 046572A1
- Authority
- AR
- Argentina
- Prior art keywords
- nitric oxide
- transcription
- heart disease
- oxide synthase
- stem
- Prior art date
Links
- 238000013518 transcription Methods 0.000 title abstract 6
- 230000035897 transcription Effects 0.000 title abstract 6
- 238000002659 cell therapy Methods 0.000 title abstract 4
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 abstract 6
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 abstract 6
- 239000003623 enhancer Substances 0.000 abstract 4
- 208000031225 myocardial ischemia Diseases 0.000 abstract 3
- 210000000130 stem cell Anatomy 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005714 functional activity Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- BOFMSBVSYVESTM-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-4-fluorobenzamide Chemical group C1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2C1 BOFMSBVSYVESTM-UHFFFAOYSA-N 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Uso de compuestos que mejoran la transcripción de sintasa de oxido nítrico endotelial (eNOS) para tratar células estaminales y madre en la terapia celular de pacientes con enfermedades cardiacas isquemicas tales como enfermedad cardiaca o cardiomiopatia isquemica. El tratamiento de tales células que se aíslan, por ejemplo, de medula ósea, con un mejorador de la transcripción de eNOS antes de su administración aumenta su actividad funcional y mejora la neovascularizacion del corazón y la regeneración cardiaca. Reivindicación 3: El uso según la reivindicación 1 y/o la reivindicación 2, en el que el mejorador de transcripción de sintasa de oxido nítrico endotelial se selecciona entre 4-fluoro-N-(indan-2-il) benzamida e indan-2- ilamida de ácido 2,2-difluorobenzo[1,3] dioxol-5-carboxilico. Reivindicación 8: Un procedimiento para producir un medicamento para tratar células estaminales y/o madre en la terapia celular de un paciente con una enfermedad cardiaca isquemica, que comprende emplear un mejorador de transcripción de sintasa de oxido nítrico endotelial. Reivindicación 10: Un medicamento para tratar células estaminales y/o madre en la terapia celular de un paciente con una enfermedad cardiaca isquemica, que comprende un mejorador de transcripción de sintasa de oxido nítrico endotelial.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03025512A EP1529525A1 (en) | 2003-11-06 | 2003-11-06 | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046572A1 true AR046572A1 (es) | 2005-12-14 |
Family
ID=34429288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104050A AR046572A1 (es) | 2003-11-06 | 2004-11-04 | Uso de mejoradores de la transcripcion de enos en la terapia celular de enfermedades cardiacas isquemicas |
Country Status (22)
| Country | Link |
|---|---|
| EP (3) | EP1529525A1 (es) |
| JP (1) | JP4705581B2 (es) |
| KR (1) | KR101133943B1 (es) |
| CN (1) | CN100563643C (es) |
| AR (1) | AR046572A1 (es) |
| AT (1) | ATE454143T1 (es) |
| AU (1) | AU2004286776B2 (es) |
| BR (1) | BRPI0416313A (es) |
| CA (1) | CA2544632C (es) |
| CY (1) | CY1112015T1 (es) |
| DE (1) | DE602004025024D1 (es) |
| DK (1) | DK1682111T3 (es) |
| ES (1) | ES2339252T3 (es) |
| HK (1) | HK1095527A1 (es) |
| IL (1) | IL174807A (es) |
| PE (1) | PE20050486A1 (es) |
| PL (1) | PL1682111T3 (es) |
| PT (1) | PT1682111E (es) |
| SI (1) | SI1682111T1 (es) |
| TW (1) | TW200528119A (es) |
| UY (1) | UY28605A1 (es) |
| WO (1) | WO2005044249A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1529525A1 (en) | 2003-11-06 | 2005-05-11 | Aventis Pharma Deutschland GmbH | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases |
| EP1930346B1 (en) | 2005-08-29 | 2011-10-19 | Japan Science and Technology Agency | Antibody produced using ostrich and method for production thereof |
| WO2014042292A1 (ko) * | 2012-09-12 | 2014-03-20 | 연세대학교 산학협력단 | 단백질 인산화효소 c 활성화제를 포함하는 줄기세포 부착 촉진용 조성물 및 줄기세포의 부착 촉진 방법 |
| GB201601301D0 (en) * | 2016-01-25 | 2016-03-09 | Takeda Pharmaceutical | Novel compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1171165T3 (da) * | 1999-03-30 | 2007-09-03 | Ran Kornowski | Injektion af autolog knoglemarv i myokardiet |
| PE20020856A1 (es) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020870A1 (es) * | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| EP1529525A1 (en) | 2003-11-06 | 2005-05-11 | Aventis Pharma Deutschland GmbH | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases |
-
2003
- 2003-11-06 EP EP03025512A patent/EP1529525A1/en not_active Withdrawn
-
2004
- 2004-10-22 EP EP09180832.9A patent/EP2198861B1/en not_active Expired - Lifetime
- 2004-10-22 BR BRPI0416313-3A patent/BRPI0416313A/pt not_active IP Right Cessation
- 2004-10-22 AU AU2004286776A patent/AU2004286776B2/en not_active Ceased
- 2004-10-22 EP EP04818113A patent/EP1682111B1/en not_active Expired - Lifetime
- 2004-10-22 JP JP2006537141A patent/JP4705581B2/ja not_active Expired - Fee Related
- 2004-10-22 ES ES04818113T patent/ES2339252T3/es not_active Expired - Lifetime
- 2004-10-22 DE DE602004025024T patent/DE602004025024D1/de not_active Expired - Lifetime
- 2004-10-22 KR KR1020067008754A patent/KR101133943B1/ko not_active IP Right Cessation
- 2004-10-22 PL PL04818113T patent/PL1682111T3/pl unknown
- 2004-10-22 WO PCT/EP2004/011944 patent/WO2005044249A1/en active Search and Examination
- 2004-10-22 DK DK04818113.5T patent/DK1682111T3/da active
- 2004-10-22 PT PT04818113T patent/PT1682111E/pt unknown
- 2004-10-22 CN CNB2004800328468A patent/CN100563643C/zh not_active Expired - Fee Related
- 2004-10-22 CA CA2544632A patent/CA2544632C/en not_active Expired - Fee Related
- 2004-10-22 AT AT04818113T patent/ATE454143T1/de active
- 2004-10-22 SI SI200431368T patent/SI1682111T1/sl unknown
- 2004-11-02 PE PE2004001057A patent/PE20050486A1/es not_active Application Discontinuation
- 2004-11-04 AR ARP040104050A patent/AR046572A1/es unknown
- 2004-11-04 TW TW093133554A patent/TW200528119A/zh unknown
- 2004-11-05 UY UY28605A patent/UY28605A1/es unknown
-
2006
- 2006-04-05 IL IL174807A patent/IL174807A/en not_active IP Right Cessation
-
2007
- 2007-03-08 HK HK07102565.4A patent/HK1095527A1/xx not_active IP Right Cessation
-
2010
- 2010-02-10 CY CY20101100127T patent/CY1112015T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1682111B1 (en) | 2010-01-06 |
| CY1112015T1 (el) | 2015-11-04 |
| EP2198861B1 (en) | 2014-06-25 |
| ATE454143T1 (de) | 2010-01-15 |
| HK1095527A1 (en) | 2007-05-11 |
| DK1682111T3 (da) | 2010-04-26 |
| IL174807A0 (en) | 2008-04-13 |
| WO2005044249A1 (en) | 2005-05-19 |
| PL1682111T3 (pl) | 2010-06-30 |
| UY28605A1 (es) | 2005-05-31 |
| EP1529525A1 (en) | 2005-05-11 |
| EP2198861A3 (en) | 2010-12-15 |
| KR101133943B1 (ko) | 2012-04-13 |
| AU2004286776B2 (en) | 2010-05-27 |
| CA2544632C (en) | 2012-09-04 |
| JP2007509873A (ja) | 2007-04-19 |
| CN100563643C (zh) | 2009-12-02 |
| AU2004286776A1 (en) | 2005-05-19 |
| CA2544632A1 (en) | 2005-05-19 |
| SI1682111T1 (sl) | 2010-04-30 |
| ES2339252T3 (es) | 2010-05-18 |
| CN1878544A (zh) | 2006-12-13 |
| JP4705581B2 (ja) | 2011-06-22 |
| PE20050486A1 (es) | 2005-10-06 |
| BRPI0416313A (pt) | 2006-12-26 |
| DE602004025024D1 (de) | 2010-02-25 |
| TW200528119A (en) | 2005-09-01 |
| IL174807A (en) | 2011-05-31 |
| EP2198861A2 (en) | 2010-06-23 |
| KR20060108658A (ko) | 2006-10-18 |
| PT1682111E (pt) | 2010-02-10 |
| EP1682111A1 (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119951T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv | |
| JP2019142862A (ja) | 医学的状態と疾患を治療するようにプラズマ状態の一酸化窒素を利用する装置 | |
| ATE457722T1 (de) | Verbesserte zelltherapie und gewebsregeneration mittels stosswellen bei patienten mit kardiovaskulären and neurologischen krankheiten | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| WO2005034843A3 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| ES2156421T3 (es) | Composiciones utiles para la transferencia de polinucleotidos terapeuticamente activos a una celula diana y su utilizacion en la terapia genica. | |
| BR112022008744A2 (pt) | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| AR082953A1 (es) | Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes | |
| RU2017139096A (ru) | Композиция, содержащая биосовместимый матрикс, способ получения композиции | |
| DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| HK1205677A1 (en) | Mesenchymal stem cells and uses therefor | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| AR046572A1 (es) | Uso de mejoradores de la transcripcion de enos en la terapia celular de enfermedades cardiacas isquemicas | |
| TW200501934A (en) | Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set | |
| AR044315A1 (es) | Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido | |
| BR112021019139A2 (pt) | Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry | |
| NO20071238L (no) | Fremgangsmater for leging av skader ved human IL-18 administrering | |
| RU2577950C1 (ru) | Способ стимуляции заживления дермальных ожогов | |
| PT1585513E (pt) | Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia | |
| RU2006107456A (ru) | Способ лечения кожных стрий | |
| KR101673318B1 (ko) | 은나노 물질로 처리된 중간엽 줄기세포 또는 그 배양액을 유효성분으로 포함하는 상처 치료용 세포치료제 조성물 | |
| RU2010141597A (ru) | Способ лечения онкологических заболеваний | |
| RU2012114023A (ru) | Способ стимуляции эндогенной продукции цитокинов и гемопоэтических факторов | |
| DE60222633D1 (de) | Verwendung von matrixprotein für gesteuerte geweberegenerationen | |
| EA201900418A1 (ru) | Средство для терапии раневых или ожоговых поражений кожи |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |